Artificial Intelligence-based Voice Assessment of Children and Adults Respiratory Conditions
Condition(s) studied
Investigational drug(s) / intervention(s)
Wevosys acoustic analysis: Recording of voice signal of subjects enrolled
Study summary
Acute and Chronic respiratory conditions represent a leading cause of death and morbidity in children and adults worldwide. The diagnosis of bronchiolitis and asthmatic exacerbations is based on clinical, and mostly subjective, clinical parameters with moderately accurate prognostic role. Patients undergoing neck radiotherapy need invasive assessments of larynx. A simple biomarker like Voice may facilitate the management of these conditions. Recent studies showed that VOICE may be used as a good and easy biomarker to diagnose and monitor several respiratory and non-respiratory conditions. A prospective study aimed to collected VOICE and other clinical data in adults and children with common acute and chronic respiratory conditions at high impact on healthcare systems will be performed. VOICE-omic data will be linked with clinical findings generating data integration, using artificial intelligence technology to develop a Decision Support Systems to provide the basis for non-invasive personalised early recognition, diagnosis, monitoring and prognosis of patients with these conditions.
Eligibility
Primary outcome measure(s)
- Acoustic parameters of voice signal in children — enrollment; 24 and 48 hours post-therapy; 24 months
Fundamental frequency (F0), measured in Hertz, is defined as the number of times a sound wave produced by the vocal cords repeats during a given time period, it is also the number of cycles of opening/closure of the glottis. - Acoustic parameters of voice signal in children — enrollment; 24 and 48 hours post-therapy; 24 months
Jitter (%) is the variation from cycle of opening/closure of the glottis to cycle. - Acoustic parameters of voice signal in children — enrollment; 24 and 48 hours post-therapy; 24 months
Shimmer (%) relates to the amplitude variation of the sound wave. - Acoustic parameters of voice signal in children — enrollment; 24 and 48 hours post-therapy; 24 months
NHR (decibel) that is an assessment of the ratio between periodic components and non periodic component comprising a segment of voiced speech. - Acoustic parameters of voice signal in adults affected by acute or chronic upper aerodigestive diseases — enrollment; 24 and 48 hours post-therapy; 24 months
Fundamental frequency (F0), measured in Hertz, is defined as the number of times a sound wave produced by the vocal cords repeats during a given time period, it is also the number of cycles of opening/closure of the glottis. - Acoustic parameters of voice signal in adults affected by acute or chronic upper aerodigestive diseases — enrollment; 24 and 48 hours post-therapy; 24 months
Jitter (%) is the variation from cycle of opening/closure of the glottis to cycle; Shimmer (%) relates to the amplitude variation of the sound wave. - Acoustic parameters of voice signal in adults affected by acute or chronic upper aerodigestive diseases — enrollment; 24 and 48 hours post-therapy; 24 months
Shimmer (%) relates to the amplitude variation of the sound wave. - Acoustic parameters of voice signal in adults affected by acute or chronic upper aerodigestive diseases — enrollment; 24 and 48 hours post-therapy; 24 months
NHR (decibel) that is an assessment of the ratio between periodic components and non periodic component comprising a segment of voiced speech. - Pediatric Dyspnea Scale — enrollment; 24 hours and 48 hours post-therapy; 24 months
The child is asked to answer the question "How much difficulty are you having breathing?" by choosing the column that best corresponds to his or her perceived symptoms (range from 0 not trouble at all to 7 very much trouble) - Voice Handicap Index score in adults affected by acute or chronic upper aerodigestive diseases — enrollment; 24 hours and 48 hours after therapy; 24 months
The Voice Handicap Index is self-assessment instrument useful for quantifying the biopsychosocial impact of a voice disorder. It consists of 30 items. The total score ranges from 0 (no impact of dysphonia) to 120 (the worst possibile impact of dysphonia) - Acoustic parameters of voice signal in adults underwent radiotherapy — enrollment; on the 30th day of radiotherapy
Fundamental frequency (F0), measured in Hertz, is defined as the number of times a sound wave produced by the vocal cords repeats during a given time period, it is also the number of cycles of opening/closure of the glottis. - Acoustic parameters of voice signal in adults underwent radiotherapy — enrollment; on the 30th day of radiotherapy
Jitter (%) is the variation from cycle of opening/closure of the glottis to cycle. - Acoustic parameters of voice signal in adults underwent radiotherapy — enrollment; on the 30th day of radiotherapy
Shimmer (%) relates to the amplitude variation of the sound wave. - Acoustic parameters of voice signal in adults underwent radiotherapy — enrollment; on the 30th day of radiotherapy
NHR (decibel) that is an assessment of the ratio between periodic components and non periodic component comprising a segment of voiced speech. - Voice Handicap Index score in adults who underwent radiotherapy — enrollment; on the 30th day of radiotherapy
The Voice Handicap Index is self-assessment instrument useful for quantifying the biopsychosocial impact of a voice disorder. It consists of 30 items. The total score ranges from 0 (no impact of dysphonia) to 120 (the worst possibile impact of dysphonia) - Dysphagia Handicap Index in adults who underwent radiotherapy — enrollmentt; on the 30th day of radiotherapy
The Dysphagia Handicap Index is a 25-item measure of Health-related Quality of Life for patients with oropharyngeal dysphagia of heterogeneous etiologies. The total score ranges from 0 to 100, with lower scores indicating better swallowing-related QoL.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Jacopo Galli | Roma | Italy | |
| Maria Raffaella Marchese | Roma | Italy |
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06630078 on ClinicalTrials.gov ↗ ← All trials in Italy